Aquarate Partners With Wirral Council
Aquarate Ltd, which is part of the Deepbridge Life Sciences EIS fund, has recently announced a new partnership with Wirral Council to offer digital hydration monitoring across care homes.
Aquarate Ltd, which is part of the Deepbridge Life Sciences EIS fund, has recently announced a new partnership with Wirral Council to offer digital hydration monitoring across care homes.
As of the 25th April 2022, Deepbridge Capital is proud to announce that it has deployed a record £31.5 million into early-stage technology and life sciences companies during the 2021/22 tax year, up from £29.4 million in 2020/21.
GenoME Diagnostics, an investee company within Deepbridge's Life Sciences SEIS portfolio has recently won a £50,000 award that is to be given to Shannon Beattie (CEO - GenoME Diagnostics) as part of the celebrations marking International Women’s Day on March 8th 2022, which will be used to aid early detection of ovarian cancer.
One of Deepbridge Capital's Life Sciences Investment Managers, Ben Carter, recently spoke to IFA Magazine about the role of an investment manager and goes into more detail of the dealflow, networks and sector specific expertise of the Deepbridge Life Sciences EIS portfolio.
FluoretiQ, which is part of the Deepbridge Life Sciences EIS portfolio, as of February 21st 2022, has announced the completion of a £1.1 million, pre-series A investment. The funding round was led by Deepbridge Capital, with significant participation from MAINStream, OION, SAIC and existing investors.
Deepbridge Capital has been shortlisted for the Deal of the Year (Transaction size below £2.5 million) Award at the upcoming 2022 Insider Media, Northern Ireland Dealmakers Awards.
Hy-genie, a portfolio company within the Deepbridge Life Sciences EIS fund, was a worthy winner of Business Cloud's MedTech 50 innovation ranking last year - with the help from Alder Hey Children's Hospital in its progress.
Deepbridge Capital has deployed over £50 million of capital into UK life sciences companies.
The Deepbridge Life Sciences EIS was launched in 2017 as our first life sciences focused EIS fund, providing private investors with access to a portfolio of early-stage investee companies across the biopharmaceutical, biotechnology, medical technology and digital healthcare sectors.
Deepbridge would like to introduce our new EIS Product Overview Brochures; giving you a chance to look at both our EIS propositions, The Deepbridge Technology Growth EIS and The Deepbridge Life Sciences EIS, in a more summarised, yet informative, manner.
As well as outlining the opportunity, investment strategy and key tax benefits of the propositions, example portfolio companies are given to highlight the types of companies that Deepbridge seek to invest in.
Deepbridge would like to introduce our new SEIS Product Overview Brochures; giving you a chance to look at both our SEIS propositions, The Deepbridge Innovation SEIS and The Deepbridge Life Sciences SEIS, in a more summarised, yet informative, manner.